New drugs for medical management of uterine fibroids such as selective progesterone receptor modulators and oral GnRH antagonists are associated with a 50–60% reduction in fibroid size, but larger fibroids tend to persist and may continue to cause symptoms. This evidence concerns the gene PGR and uterine corpus leiomyoma.